| Autor: |
Naruoka A; Drug Discovery and Development Division, Shizuoka Cancer Center Research Institute., Ohnami S; Cancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute., Nagashima T; Cancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute.; SRL Inc., Serizawa M; Drug Discovery and Development Division, Shizuoka Cancer Center Research Institute., Hatakeyama K; Medical Genetics Division, Shizuoka Cancer Center Research Institute., Ohshima K; Medical Genetics Division, Shizuoka Cancer Center Research Institute., Ohnami S; Cancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute., Urakami K; Cancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute., Horiuchi Y; Division of Genetic Counseling, Shizuoka Cancer Center Hospital., Kiyozumi Y; Division of Genetic Counseling, Shizuoka Cancer Center Hospital., Matsubayashi H; Division of Genetic Counseling, Shizuoka Cancer Center Hospital., Abe M; Division of Pathology, Shizuoka Cancer Center Hospital., Ohishi T; Division of Pathology, Shizuoka Cancer Center Hospital., Kameya T; Division of Pathology, Shizuoka Cancer Center Hospital., Sugino T; Division of Pathology, Shizuoka Cancer Center Hospital., Onitsuka T; Division of Head and Neck Surgery, Shizuoka Cancer Center Hospital., Isaka M; Division of Thoracic Surgery, Shizuoka Cancer Center Hospital., Ohde Y; Division of Thoracic Surgery, Shizuoka Cancer Center Hospital., Sugiura T; Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center Hospital., Ito T; Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center Hospital., Uesaka K; Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center Hospital., Akiyama Y; Immunotherapy Division, Shizuoka Cancer Center Research Institute., Kusuhara M; Shizuoka Cancer Center., Yamaguchi K; Shizuoka Cancer Center. |
| Abstrakt: |
Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant tumor syndrome. This hereditary cancer is caused by germline variants in MEN1. Two patients with MEN1 were identified via whole exome sequencing and gene expression profile analysis, conducted for 5,063 patients with various types of cancers. We obtained multiple tumors from each patient; tumors derived from these two MEN1 patients had a loss of the normal MEN1 allele and frequently chromosomal copy number changes. Thus, we investigated whether structural variants were present in the MEN1 patient genomes. Whole-genome sequencing revealed no catastrophic rearrangements, and the tumor samples had very low somatic variants. The two patients had germline variants in MEN1 and some chromosomal copy number changes including on chromosome 11. The only pathogenic variant detected was the MEN1 germline variant, and chromosomal rearrangements led to tumorigenesis in somatic cells. Furthermore, the MEN1 tumor samples displayed a specific signature characterized by T:A>C:G transition. Studies of multiple tumors obtained from single patients are rare in hereditary cancer syndromes, and our results provide insights that the second hit of the tumor suppressor gene MEN1 may be caused by a gross genome rearrangement, not a small insertion and deletion, nor a change in epigenetic regulation. |
